3-Ethoxybenzamide is an alkoxybenzamide compound with antibacterial activity and a FtsZ inhibitor that can cross the blood-brain barrier. 3-Ethoxybenzamide distributes widely and rapidly in vivo, rapidly reaches equilibrium between various tissues and blood, and is linearly taken up by hepatocytes. 3-Ethoxybenzamide is completely dependent on hepatic microsomal oxidation for clearance, with salicylamide as its major metabolite. 3-Ethoxybenzamide can be used for the study of bacterial infections [1] [2].
In Vivo, 3-Ethoxybenzamide (10-80 mg/kg; i.v.; single bolus) simulated plasma and tissue concentrations in healthy male albino rabbits show strong agreement with observed values at 10 mg/kg and 20 mg/kg intravenous bolus doses, though the 80 mg/kg dose terminal elimination phase cannot be accurately predicted by the model[1]. 3-Ethoxybenzamide (20-100 mg/kg; i.v.; single bolus) simulated plasma and tissue concentrations in healthy 250 g rats show reasonable agreement with observed values across 20 mg/kg, 50 mg/kg, and 100 mg/kg intravenous bolus doses, with minor discrepancies in small intestine and muscle tissue profiles[1].
In Vitro, 3-Ethoxybenzamide (0.1-1.0 mM; 0.5-10 min) rapidly reaches equilibrium with rat erythrocytes, and its whole blood-plasma partition coefficient equals 1 at all tested concentrations[1]. 3-Ethoxybenzamide undergoes deethylation in rat liver microsomes, with the corrected kinetic parameter being Vmax1=0.124 μmol/min/g[1]. 3-Ethoxybenzamide (500-2000 μg/mL) inhibits the bacterial growth of Bacillus subtilis 168, with an MIC of 2000 μg/mL, and induces cell division inhibition at a concentration of 500 μg/mL[2].
References:
[1]. Lin JH, et al. Physiological pharmacokinetics of ethoxybenzamide based on biochemical data obtained in vitro as well as on physiological data. J Pharmacokinet Biopharm. 1982;10(6):649-661.
[2]. Czaplewski LG, et al. Antibacterial alkoxybenzamide inhibitors of the essential bacterial cell division protein FtsZ. Bioorg Med Chem Lett. 2009;19(2):524-527.
In Vivo, 3-Ethoxybenzamide (10-80 mg/kg; i.v.; single bolus) simulated plasma and tissue concentrations in healthy male albino rabbits show strong agreement with observed values at 10 mg/kg and 20 mg/kg intravenous bolus doses, though the 80 mg/kg dose terminal elimination phase cannot be accurately predicted by the model[1]. 3-Ethoxybenzamide (20-100 mg/kg; i.v.; single bolus) simulated plasma and tissue concentrations in healthy 250 g rats show reasonable agreement with observed values across 20 mg/kg, 50 mg/kg, and 100 mg/kg intravenous bolus doses, with minor discrepancies in small intestine and muscle tissue profiles[1].
In Vitro, 3-Ethoxybenzamide (0.1-1.0 mM; 0.5-10 min) rapidly reaches equilibrium with rat erythrocytes, and its whole blood-plasma partition coefficient equals 1 at all tested concentrations[1]. 3-Ethoxybenzamide undergoes deethylation in rat liver microsomes, with the corrected kinetic parameter being Vmax1=0.124 μmol/min/g[1]. 3-Ethoxybenzamide (500-2000 μg/mL) inhibits the bacterial growth of Bacillus subtilis 168, with an MIC of 2000 μg/mL, and induces cell division inhibition at a concentration of 500 μg/mL[2].
References:
[1]. Lin JH, et al. Physiological pharmacokinetics of ethoxybenzamide based on biochemical data obtained in vitro as well as on physiological data. J Pharmacokinet Biopharm. 1982;10(6):649-661.
[2]. Czaplewski LG, et al. Antibacterial alkoxybenzamide inhibitors of the essential bacterial cell division protein FtsZ. Bioorg Med Chem Lett. 2009;19(2):524-527.